RxDoctor Payments Data

Nachiket Patel, MD

Cardiovascular Disease · Toms River, NJNPI 1104999036

Payments from drug & device makers

$3,244in general payments, 2019–2025

Across 83 payments — averaging $39.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$873
  • Abbott$609
  • Edwards Lifesciences$585
  • Novartis$322
  • Philips North America LLC$320
  • Boston Scientific$141
  • plus $394 from 6 others

What the payments were for

  • Travel & lodging$76624%
  • Food & beverage$2,47876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,244 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$318,936
Medicare patients
1,174
Services billed
4,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$113,838
XareltoRivaroxaban24$20,987
EntrestoSacubitril/Valsartan18$20,611
BrilintaTicagrelor16$14,532
Atorvastatin Calcium147$1,657
Metoprolol Succinate97$1,353
ClopidogrelClopidogrel Bisulfate82$929
Valsartan13$905
Nifedipine ErNifedipine29$822
Enalapril Maleate36$810
Hydralazine Hcl33$807
Isosorbide Mononitrate ErIsosorbide Mononitrate48$787
Flecainide Acetate12$772
Losartan Potassium39$729
Rosuvastatin Calcium32$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$113,838100 claims
Johnson & JohnsonXarelto$27$20,98724 claims
NovartisEntresto$322$20,61118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →